This is a working overview of triagonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
This problem can be avoided by fusing an affinity tag to self-cleavable inteins in a controlled environment. The first generation of expression vectors of this kind used modified Saccharomyces cerevisiae VMA (Sce VMA) intein. Chong et al. used a chitin binding domain (CBD) from Bacillus circulans as an affinity tag, and fused this tag with a modified Sce VMA intein. The modified intein undergoes a self-cleavage reaction at its N-terminal peptide linkage with 1,4-dithiothreitol (DTT), β-mercaptoethanol (β-ME), or cystine at low temperatures over a broad pH range. After expressing the recombinant protein, the cell homogenate is passed through the column containing chitin. This allows the CBD of the chimeric protein to bind to the column. Furthermore, when the temperature is lowered and the molecules described above pass through the column, the chimeric protein undergoes self-splicing and only the target protein is eluted. This novel technique eliminates the need for a proteolysis step, and modified Sce VMA stays in column attached to chitin through CBD. Recently inteins have been used to purify proteins based on self aggregating peptides. Elastin-like polypeptides (ELPs) are a useful tool in biotechnology. Fused with target protein, they tend to form aggregates inside the cells. This eliminates the chromatographic step needed in protein purification.
=== United States === In August 2003, The a2 Milk Company exclusively licensed patent and trademark rights to US-based Ideasphere Incorporated (ISI) to market A1 protein-free products in North America. ISI acquired Twinlab in September 2003, followed by another string of acquisitions in the dietary supplement market. In June 2005, ISI and A2 Corporation agreed to form a joint venture, a2 Milk Company LLC. In April 2007 A2 Corporation announced a deal in which the joint venture would license rights to the Original Foods Company, whose branding the A1 protein-free product would carry, and in which the product would be sold in several midwestern states through the Hy-Vee supermarket chain. In A2 Corporation's 2009 Annual Report, the company announced that the joint venture had regained all rights to the US market through a settlement with the Original Foods Company. In 2010 The a2 Milk Company bought out more than 99% of ISI's share in the joint venture. The a2 Milk Company is the owner of US trademarks that include the term A2 and/or A2 MILK for milk and other dairy related products, including a trademark for "a2 MILK." The a2 Milk Company announced in 2018 that it now had around 9,000 stores in its distribution network in the United States that sell its a2 and a2 MILK branded products.
=== Ma–Me === Alan MacDiarmid (1927–2007), American-New Zealand chemist who discovered conductive polymers, 2000 Nobel Prize in Chemistry Carolina Henriette Mac Gillavry (1904–1993), Dutch chemist and crystallographer known for discoveries on the use of diffraction in crystallography Roderick MacKinnon (born 1956), American biophsicist known for work on ion channels; 2003 Nobel Prize in Chemistry Pierre Macquer (1718–1784), French chemist known for Dictionnaire de chymie Rudolph A. Marcus (1923–2026), Canadian chemist known for work on the theory of electron transfer reactions; 1992 Nobel Prize in Chemistry Jacob A. Marinsky (1918–2005), American chemist, co-discovered the element promethium Jean Charles Galissard de Marignac (1817–1894), Swiss chemist who discovered ytterbium and co-discovered gadolinium Vladimir Vasilevich Markovnikov (1838–1904), Russian chemist known for Markovnikov's rule describing addition reactions of hydrogen halides and alkenes Tobin J. Marks (born 1944), American inorganic chemist and materials scientist known for work in polymerization catalysts Alan G.
The epithelial lining of the mucosa, differs along the gastrointestinal tract. The epithelium is described as stratified if it consists of multiple layers of cells, and simple if it is made up of one layer of cells. Terms used to describe the shape of the cells in it - columnar if column-shaped, and squamous if flat.
Sources: en.wikipedia.org
Under Xi, China's official military budget has more than doubled, reaching a record $282 billion in 2026. Though predating Xi, his administration has taken a more assertive stance towards maritime affairs, and has boosted CCP control over the maritime security forces. The PLA Navy has grown rapidly under Xi, with China adding more warships, submarines, support ships and major amphibious vessels from 2014 to 2019 than the entire number of ships serving in the United Kingdom's fleet. Aircraft carriers Shandong and Fujian entered into service under Xi in 2019 and 2025 respectively. In 2017, China established the navy's first overseas base in Djibouti. Xi has also undertaken an expansion of China's nuclear arsenal, with him calling China to "establish a strong system of strategic deterrence." The Federation of American Scientists (FAS) has estimated China's total nuclear arsenal to be 600 in 2025, with the US Department of Defense estimating that China's arsenal could reach 1,000 by 2030.
==== Increased throughput ==== While DMF systems cannot match the same throughput achieved by some liquid handling pipetting robots, or by some droplet-based microfluidic systems, there are still throughput advantages when compared to conventional methods carried out manually.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\mu N-\mu S-{\frac {\beta IS}{N}}\\[8pt]{\frac {dE}{dt}}&={\frac {\beta IS}{N}}-(\mu +a)E\\[8pt]{\frac {dI}{dt}}&=aE-(\gamma +\mu )I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R.\end{aligned}}}
29 September The kārearea is named Bird of the Year for 2025. The government announces a reform of the earthquake-prone building classification system which reduces the amount of buildings nationwide being classed as earthquake-prone by 55%. 30 September: Carter Holt Harvey confirms plans to close its Tokoroa plywood plant in November 2025, affecting 119 jobs. A measles case linked to international travel is reported in Queenstown, bringing the total number of cases to five.
== SPE and chromatography == SPE is in fact a method of chromatography, in the sense of having a mobile phase, carrying mixtures through a stationary phase, packed inside a column. The chromatographic process is harnessed to create a solid-liquid extractive technique—allowing separation of a mixture of components by taking advantage of large differences between the solid and liquid phase Keq, or equilibrium constant, for each component in the mixture. The chemical considerations for the selection of stationary and mobile phases are similar to those for liquid column chromatography and many of the adsorbents/materials used are the same. The theory, procedures, and aims are different, however, and as an extractive technique it has a unique niche in modern chemical science.
Sources: en.wikipedia.org
The dangers of radium were recognized in the early 1920s and first described in 1924 by New York dentist and oral surgeon Theodor Blum (1883-1962). He was particularly aware of the use of radium in the watch industry, where it was used for luminous dials. He published an article on the clinical picture of the so-called radium jaw. He observed this disease in female patients who, as dial painters, came into contact with luminous paint whose composition was similar to Radiomir, a luminous material invented in 1914 consisting of a mixture of zinc sulfide and radium bromide. As they painted, they used their lips to form the tip of the phosphorus-laden brush into the desired pointed shape, and this is how the radioactive radium entered their bodies. In the U.S. and Canada alone, about 4,000 workers were affected over the years. In retrospect, the factory workers were called the Radium Girls. They also played with the paint, painting their fingernails, teeth and faces. This made them glow at night to the surprise of their companions.
== Laboratory methods == A number of laboratory methods have been developed for cell-free fetal DNA screening for genetic defects have been developed. The main ones are (1) massively parallel shotgun sequencing (MPSS), (2) targeted massive parallel sequencing (t-MPS) and (3) single nucleotide polymorphism (SNP) based approach. A maternal peripheral blood sample is taken by venesection at about ten weeks gestation.
=== Freight transport === South Africa's logistics sector consists of a combination of freight transport routes, including those by road, rail, air, and sea, which are shared by private and state-owned logistics companies. State-owned Transnet owns, and for the most part manages, South Africa's rail and seaport assets. As of 2023, the total value of those assets was R7.5 billion.
While the production of alcohol is the most noteworthy by-product of yeast metabolism from a winemaking perspective, there are a number of other products that yeast produce that can be also influence the resulting wine. This includes glycerol which is produced when an intermediate of the glycolysis cycle (dihydroxyacetone) is reduced to "recharge" the NADH enzyme needed to continue other metabolic activities. This is usually produced early in the fermentation process before the mechanisms to reduce acetaldehyde into ethanol to recharge NADH becomes the cell's primary means of maintaining redox balance. As glycerol contributes increased body and a slightly sweet taste without increasing the alcohol level of the wine, some winemakers try to intentionally favor conditions that would promote glycerol production in wine. This includes selecting yeast strains that favor glycerol production (or allowing some wild yeast like Kloeckera and Metschnikowia to ferment), increased oxygen exposure and aeration as well as fermenting at higher temperatures. Glycerol production is also encouraged if most available acetaldehyde is made unavailable by binding with bisulfite molecules in the wine, but it would take a substantial amount of sulfur dioxide addition (far beyond legal limits) to prolong glycerol production beyond just these very nascent stages of fermentation. Other by-products of yeast include:
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.